Tarceva (erlotinib), a new ORAL treatment for non-small cell lung cancer (NSCLC)

January 2005

You'll soon see Tarceva (erlotinib), a new ORAL treatment for non-small cell lung cancer (NSCLC).

It increases survival in patients with advanced NSCLC.

Think of it as similar to gefitinib (Iressa). These drugs target growth factors that stimulate tumor growth.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

raising questions about FDA's drug approval and surveillance process
Diabetes Reps will be touting evidence that suggests carvedilol is better than metoprolol for diabetes patients
Fibromyalgia what really works for fibromyalgia
Cardiology Reps will be saying that amlodipine (Norvasc) reduces the risk of cardiovascular events
Cardiology BiDil will be the first drug approved specifically for African Americans
Light therapy is often as effective as antidepressants for seasonal affective disorder (SAD)
Ritalin, Adderall, and other stimulants to enhance test scores
Antiarrhythmics flecainide (Tambocor) or propafenone (Rythmol) written "take as needed for atrial fibrillation"
Multiple Sclerosis Tysabri (tie-SAB-ree), the latest treatment for multiple sclerosis (MS)
Multiple Sclerosis Aricept and other cholinesterase inhibitors for patients with multiple sclerosis
Women's Health the risk of bone loss in women using Depo-Provera
Women's Health whether testosterone is appropriate for treating sexual dysfunction in women
Hematology & Oncology More women with EARLY breast cancer will be treated with an aromatase inhibitor
Hematology & Oncology Tarceva (erlotinib), a new ORAL treatment for non-small cell lung cancer (NSCLC)
Supplements DHEA for weight loss
Practice End of year is a good time to reflect on trustworthy drug information that is relevant to practice.